News

Background & AimCardiac amyloidosis is an infiltrative cardiomyopathy associated with significant morbidity and mortality. Frailty, a biologic syndrome of…

Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug.BridgeBio’s…

Cardiac amyloidosis is a condition where abnormal protein deposits build up in the heart, making it stiff and causing it to work less effectively. One common type…

− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart…

The US Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug (PRX004) for the treatment of transthyretin-mediated amyloid…

BridgeBio Pharma announced that acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), significantly reduces serum transthyretin variability and…

Light chain (AL) amyloidosis is caused by misfolded light chains depositing in tissues in the form of fibrils, leading to organ damage  [1]. Treatment consists…

1 IntroductionSystemic light chain amyloidosis (AL) occurs due to a clonal plasma cell dyscrasia, typically with multi-system involvement and associated with a poor…

BridgeBio Pharma Inc. (BBIO), a commercial-stage biopharmaceutical company, on Monday announced new data from its Phase 3 ATTRibute-CM study of Acoramidis,…

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized yet frequently underdiagnosed cause of heart failure, particularly among older adults.…